Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00738530 · FLOW

Participant flow

A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy · Source last updated 2016-06-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Bevacizumab infusions were administered every 2 weeks at a dose of 10 milligram per kilogram (mg/kg) for 52 weeks or until disease progression or unacceptable toxicity. Interferon alfa-2a (IFN-Alfa-2A) was administered 3 times per week as a subcutaneous injection at a dose of 9 million international units (MIU) for 52 weeks or until disease progression or major toxicity.
    id
    FG000
    title
    Bevacizumab + IFN-Alfa-2A
  2. description
    Placebo matched with Bevacizumab infusions were administered every 2 weeks for 52 weeks or until disease progression or unacceptable toxicity. IFN-Alfa-2A was administered 3 times per week as a subcutaneous injection at a dose of 9 MIU for 52 weeks or until disease progression or major toxicity.
    id
    FG001
    title
    Placebo + IFN-Alfa-2A
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        220
      2. group Id
        FG001
        num Subjects
        224
      type
      Death
    2. reasons
      1. group Id
        FG000
        num Subjects
        8
      2. group Id
        FG001
        num Subjects
        6
      type
      Lost to Follow-up
    3. reasons
      1. group Id
        FG000
        num Subjects
        6
      2. group Id
        FG001
        num Subjects
        8
      type
      Withdrawal by Subject
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        327
      2. group Id
        FG001
        num Subjects
        322
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        325
      2. group Id
        FG001
        num Subjects
        316
      type
      Treated
    3. achievements
      1. group Id
        FG000
        num Subjects
        93
      2. group Id
        FG001
        num Subjects
        84
      type
      COMPLETED
    4. achievements
      1. group Id
        FG000
        num Subjects
        234
      2. group Id
        FG001
        num Subjects
        238
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
A total of 821 participants were screened for this study, and 649 of these were randomized to receive double-blind treatment.
Complete source fields
groups
  1. description
    Bevacizumab infusions were administered every 2 weeks at a dose of 10 milligram per kilogram (mg/kg) for 52 weeks or until disease progression or unacceptable toxicity. Interferon alfa-2a (IFN-Alfa-2A) was administered 3 times per week as a subcutaneous injection at a dose of 9 million international units (MIU) for 52 weeks or until disease progression or major toxicity.
    id
    FG000
    title
    Bevacizumab + IFN-Alfa-2A
  2. description
    Placebo matched with Bevacizumab infusions were administered every 2 weeks for 52 weeks or until disease progression or unacceptable toxicity. IFN-Alfa-2A was administered 3 times per week as a subcutaneous injection at a dose of 9 MIU for 52 weeks or until disease progression or major toxicity.
    id
    FG001
    title
    Placebo + IFN-Alfa-2A
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        220
      2. group Id
        FG001
        num Subjects
        224
      type
      Death
    2. reasons
      1. group Id
        FG000
        num Subjects
        8
      2. group Id
        FG001
        num Subjects
        6
      type
      Lost to Follow-up
    3. reasons
      1. group Id
        FG000
        num Subjects
        6
      2. group Id
        FG001
        num Subjects
        8
      type
      Withdrawal by Subject
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        327
      2. group Id
        FG001
        num Subjects
        322
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        325
      2. group Id
        FG001
        num Subjects
        316
      type
      Treated
    3. achievements
      1. group Id
        FG000
        num Subjects
        93
      2. group Id
        FG001
        num Subjects
        84
      type
      COMPLETED
    4. achievements
      1. group Id
        FG000
        num Subjects
        234
      2. group Id
        FG001
        num Subjects
        238
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
A total of 821 participants were screened for this study, and 649 of these were randomized to receive double-blind treatment.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice